279 related articles for article (PubMed ID: 27926932)
21. Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.
Ferrero-Poüs M; Hacène K; Bouchet C; Le Doussal V; Tubiana-Hulin M; Spyratos F
Clin Cancer Res; 2000 Dec; 6(12):4745-54. PubMed ID: 11156229
[TBL] [Abstract][Full Text] [Related]
22. Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature.
Tutt A; Wang A; Rowland C; Gillett C; Lau K; Chew K; Dai H; Kwok S; Ryder K; Shu H; Springall R; Cane P; McCallie B; Kam-Morgan L; Anderson S; Buerger H; Gray J; Bennington J; Esserman L; Hastie T; Broder S; Sninsky J; Brandt B; Waldman F
BMC Cancer; 2008 Nov; 8():339. PubMed ID: 19025599
[TBL] [Abstract][Full Text] [Related]
23. Combined vascular endothelial growth factor and TP53 status predicts poor response to tamoxifen therapy in estrogen receptor-positive advanced breast cancer.
Berns EM; Klijn JG; Look MP; Grebenchtchikov N; Vossen R; Peters H; Geurts-Moespot A; Portengen H; van Staveren IL; Meijer-van Gelder ME; Bakker B; Sweep FC; Foekens JA
Clin Cancer Res; 2003 Apr; 9(4):1253-8. PubMed ID: 12684392
[TBL] [Abstract][Full Text] [Related]
24. A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer.
Chanrion M; Negre V; Fontaine H; Salvetat N; Bibeau F; Mac Grogan G; Mauriac L; Katsaros D; Molina F; Theillet C; Darbon JM
Clin Cancer Res; 2008 Mar; 14(6):1744-52. PubMed ID: 18347175
[TBL] [Abstract][Full Text] [Related]
25. Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
Hopp TA; Weiss HL; Parra IS; Cui Y; Osborne CK; Fuqua SA
Clin Cancer Res; 2004 Nov; 10(22):7490-9. PubMed ID: 15569979
[TBL] [Abstract][Full Text] [Related]
26. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
27. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
28. Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.
Ramirez-Ardila DE; Helmijr JC; Look MP; Lurkin I; Ruigrok-Ritstier K; van Laere S; Dirix L; Sweep FC; Span PN; Linn SC; Foekens JA; Sleijfer S; Berns EM; Jansen MP
Breast Cancer Res Treat; 2013 May; 139(1):39-49. PubMed ID: 23592373
[TBL] [Abstract][Full Text] [Related]
29. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
30. TSC22D1 and PSAP predict clinical outcome of tamoxifen treatment in patients with recurrent breast cancer.
Meijer D; Jansen MP; Look MP; Ruigrok-Ritstier K; van Staveren IL; Sieuwerts AM; van Agthoven T; Foekens JA; Dorssers LC; Berns EM
Breast Cancer Res Treat; 2009 Jan; 113(2):253-60. PubMed ID: 18299979
[TBL] [Abstract][Full Text] [Related]
31. Identification of patients with hormone receptor-positive breast cancer who need adjuvant tamoxifen therapy for more than 5 years.
Wu CE; Chen SC; Chang HK; Lo YF; Hsueh S; Lin YC
J Formos Med Assoc; 2016 Apr; 115(4):249-56. PubMed ID: 25900861
[TBL] [Abstract][Full Text] [Related]
32. A novel MAPK-microRNA signature is predictive of hormone-therapy resistance and poor outcome in ER-positive breast cancer.
Miller PC; Clarke J; Koru-Sengul T; Brinkman J; El-Ashry D
Clin Cancer Res; 2015 Jan; 21(2):373-85. PubMed ID: 25370469
[TBL] [Abstract][Full Text] [Related]
33. Expression and splicing of the unfolded protein response gene XBP-1 are significantly associated with clinical outcome of endocrine-treated breast cancer.
Davies MP; Barraclough DL; Stewart C; Joyce KA; Eccles RM; Barraclough R; Rudland PS; Sibson DR
Int J Cancer; 2008 Jul; 123(1):85-8. PubMed ID: 18386815
[TBL] [Abstract][Full Text] [Related]
34. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
35. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
36. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.
Powles TJ; Ashley S; Tidy A; Smith IE; Dowsett M
J Natl Cancer Inst; 2007 Feb; 99(4):283-90. PubMed ID: 17312305
[TBL] [Abstract][Full Text] [Related]
37. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
38. Tumor co-expression of progranulin and sortilin as a prognostic biomarker in breast cancer.
Berger K; Rhost S; Rafnsdóttir S; Hughes É; Magnusson Y; Ekholm M; Stål O; Rydén L; Landberg G
BMC Cancer; 2021 Feb; 21(1):185. PubMed ID: 33618683
[TBL] [Abstract][Full Text] [Related]
39. Clinical significance of the nuclear receptor co-regulator DC-SCRIPT in breast cancer: an independent retrospective validation study.
Sieuwerts AM; Ansems M; Look MP; Span PN; de Weerd V; van Galen A; Foekens JA; Adema GJ; Martens JW
Breast Cancer Res; 2010; 12(6):R103. PubMed ID: 21122099
[TBL] [Abstract][Full Text] [Related]
40. Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis.
Papageorgis P; Ozturk S; Lambert AW; Neophytou CM; Tzatsos A; Wong CK; Thiagalingam S; Constantinou AI
Breast Cancer Res; 2015 Jul; 17(1):98. PubMed ID: 26208975
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
